Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma

Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma

Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of relapsed/refractory multiple myeloma. The current Food and Drug Administration approved CAR T cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel both target B cell maturation antigen (BCMA), wh...

Full description

Bibliographic Details
Main Authors: Kevin Miller, Hamza Hashmi, Sridevi Rajeeve
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-05-01
Series:Frontiers in Oncology
Subjects:
multiple myeloma
CAR T cell therapy
chimeric antigen receptor
non-BCMA
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1398902/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1398902/full

Similar Items